AI assistant
ADMA BIOLOGICS, INC. — Director's Dealing 2014
Jun 20, 2014
31261_dirs_2014-06-20_7d8b716c-e7fe-4b9a-b457-185f99dfd0eb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ADMA BIOLOGICS, INC. (ADMA)
CIK: 0001368514
Period of Report: 2014-06-18
Reporting Person: Grossman Adam S (Director, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-06-18 | Common Stock, $0.0001 par value per share | P | 1875 | $9.59 | Acquired | 602457 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.58 to $9.60 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on June 18, 2014.
F2: 580,957 of these shares are held by Hariden, LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
F3: 20,500 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
F4: These shares are being purchased by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc